Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BBOX1 | O75936 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.33 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.33 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17273638 | 0.93 | LMNA (0.41) | BBOX1LMNACYP3A4TSHRTDP1 | |
| SCHEMBL1467272 | 0.93 | LMNA (0.41) | BBOX1LMNACYP3A4TSHRTDP1 | |
| SCHEMBL1467325 | 0.91 | LMNA (0.40) | BBOX1LMNACYP3A4TSHRTDP1 | |
| SCHEMBL16037126 | 0.89 | KDM4E (0.35) | BBOX1LMNACYP3A4TSHRTDP1 | |
| SCHEMBL15212522 | 0.87 | KDM4E (0.38) | BBOX1LMNACYP3A4TSHRTDP1 | |
| SCHEMBL2146703 | 0.84 | BBOX1 (0.38) | BBOX1LMNACYP3A4TSHRTDP1 | |
| SCHEMBL3622275 | 0.82 | BBOX1 (0.42) | BBOX1LMNACYP3A4TSHRTDP1 | |
| Cyanamide SCHEMBL666990 | 0.82 | BBOX1 (0.42) | BBOX1LMNACYP3A4TSHRTDP1 | |
| Thiocyanic Acid SCHEMBL613342 | 0.82 | BBOX1 (0.42) | BBOX1LMNACYP3A4TSHRTDP1 | |
| SCHEMBL34829 | 0.82 | BBOX1 (0.52) | BBOX1LMNACYP3A4TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12172147-B2 | Catalyst composition for selective hydrogenation with improved characteristics | Sud Chemie, Inc. (US) | 2024-12-24 | — | — | US | claimed |
| US-12172148-B2 | Catalyst composition for selective hydrogenation with improved characteristics | Sud Chemie, Inc. (US) | 2024-12-24 | — | — | US | claimed |
| US-11634370-B2 | Selective hydrogenation methods | CLARIANT INTERNATIONAL LTD (CH) | 2023-04-25 | — | — | US | claimed |
| US-11623902-B2 | Selective hydrogenation methods and catalysts | CLARIANT INTERNATIONAL LTD (CH) | 2023-04-11 | — | — | US | claimed |
| CN-115768737-A | Selective hydrogenation process | 科莱恩国际有限公司 | 2023-03-07 | — | — | CN | claimed |
| CN-115715280-A | Selective hydrogenation process and catalyst | 科莱恩国际有限公司 | 2023-02-24 | — | — | CN | claimed |
| US-20210395906-A1 | ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY | CUSTOMARRAY INC (US) | 2021-12-23 | — | — | US | claimed |
| CN-113242847-A | Selective hydrogenation process | 科莱恩国际有限公司 | 2021-08-10 | — | — | CN | claimed |
| US-11059762-B2 | Selective hydrogenation methods | CLARIANT INTERNATIONAL LTD (CH) | 2021-07-13 | — | — | US | claimed |
| US-20200123081-A1 | SELECTIVE HYDROGENATION METHODS | CLARIANT INTERNATIONAL LTD (CH) | 2020-04-23 | — | — | US | claimed |
| US-20130341561-A1 | ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY | CUSTOMARRAY, INC. (US) | 2013-12-26 | — | — | US | claimed |
| US-20130102819-A1 | CATALYST COMPOSITION FOR SELECTIVE HYDROGENATION WITH IMPROVED CHARACTERISTICS | CLARIANT CORPORATION | 2013-04-25 | — | — | US | claimed |
| EP-2583751-A1 | Catalyst composition for selective hydrogenation with improved characteristics | Clariant Produkte (Deutschland) GmbH (DE) | 2013-04-24 | — | — | EP | claimed |
| US-7718579-B2 | Electrochemical deblocking using a hydrazine derivative | COMBIMATRIX CORPORATION (US) | 2010-05-18 | — | — | US | claimed |
| EP-1869061-A2 | ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY | Combimatrix Corporation (US) | 2007-12-26 | — | — | EP | claimed |
| EP-1805206-A2 | ELECTROCHEMICAL DEBLOCKING USING A HYDRAZINE DERIVATIVE | Combimatrix Corporation (US) | 2007-07-11 | — | — | EP | claimed |
| US-20070034513-A1 | Electrochemical deblocking solution for electrochemical oligomer synthesis on an electrode array | COMBIMATRIX CORPORATION | 2007-02-15 | — | — | US | claimed |
| WO-2006105037-A2 | ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY | COMBIMATRIX CORPORATION (US) | 2006-10-05 | — | — | WO | claimed |
| WO-2006031814-A2 | ELECTROCHEMICAL DEBLOCKING USING A HYDRAZINE DERIVATIVE | COMBIMATRIX CORPORATION (US) | 2006-03-23 | — | — | WO | claimed |
| US-20060054511-A1 | Electrochemical deblocking using a hydrazine derivative | CUSTOMARRAY, INC. | 2006-03-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12172147-B2 | Catalyst composition for selective hydrogenation with improved characteristics | BET1, EP300, H1-2 | BBOX1 689/4885LMNA 3071/4885CYP3A4 1780/4885 |
| US-12172148-B2 | Catalyst composition for selective hydrogenation with improved characteristics | BET1, EP300, H1-2 | BBOX1 689/4885LMNA 3071/4885CYP3A4 1780/4885 |
| US-20210395906-A1 | ELECTROCHEMICAL DEBLOCKING SOLUTION FOR ELECTROCHEMICAL OLIGOMER SYNTHESIS ON AN ELECTRODE ARRAY | DNMT1, DNASE1, DNPEP | BBOX1 796/4885LMNA 2697/4885CYP3A4 4834/4885 |
| US-11634370-B2 | Selective hydrogenation methods | KAT8, KAT7, TDO2 | BBOX1 1817/4885LMNA 4767/4885CYP3A4 1235/4885 |
| US-11623902-B2 | Selective hydrogenation methods and catalysts | KAT8, ITGAV, ASNS | BBOX1 1933/4885LMNA 4735/4885CYP3A4 1113/4885 |
| US-20130102819-A1 | CATALYST COMPOSITION FOR SELECTIVE HYDROGENATION WITH IMPROVED CHARACTERISTICS | BET1, EP300, H1-2 | BBOX1 596/4885LMNA 3311/4885CYP3A4 2204/4885 |
| US-20200123081-A1 | SELECTIVE HYDROGENATION METHODS | IDH2, CAT, ACAT1 | BBOX1 498/4885LMNA 4577/4885CYP3A4 1388/4885 |
| US-11059762-B2 | Selective hydrogenation methods | IDH2, CAT, ACAT1 | BBOX1 498/4885LMNA 4577/4885CYP3A4 1388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.